HZNP Meds. LLC v. Actavis Labs. UT, Inc.
United States Court of Appeals for the Federal Circuit
October 10, 2019, Decided
2017-2149, 2017-2152, 2017-2153, 2017-2202, 2017-2203, 2017-2206
[*682] REYNA, Circuit Judge.
HZNP Medicines LLC and Horizon Pharma USA, Inc. ("Horizon") appeal from the U.S. District Court for the District of New Jersey's judgment of invalidity and noninfringement. Actavis Laboratories UT, Inc. ("Actavis") cross-appeals the district court's judgment of nonobviousness. We affirm.
[*683] Horizon is the assignee of U.S. Patent Nos. 8,217,078 ("the '078 patent"); 9,132,110 ("the '110 patent"); 8,618,164 ("the '164 patent"); 9,168,304 ("the '304 patent"); 9,168,305 ("the '305 patent"); 8,546,450 ("the '450 patent"); 9,101,591 ("the '591 patent"); 8,563,613 ("the '613 patent"); 9,220,784 ("the '784 patent"); 8,871,809 ("the '809 patent"); 8,252,838 ("the '838 patent"); and 9,066,913 ("the '913 patent") (collectively, [**2] "the patents-at-issue" or "Horizon's patents"). The patents-at-issue generally relate to methods and compositions for treating osteoarthritis and can be divided into two groups, with the patents in each group sharing a substantially similar specification.
The first group of patents consists of method-of-use patents, including the '450, '078, '110, and '164 patents. (the "method-of-use patents"). Claim 10 of the '450 patent is illustrative of the asserted claims of the method-of-use patents:
10. A method for applying topical agents to a knee of a patient with pain, said method comprising:
applying a first medication consisting of a topical diclofenac preparation to an area of the knee of said patient to treat osteoarthritis of the knee of said patient, wherein the topical diclofenac preparation comprises a therapeutically effective amount of a diclofenac salt and 40-50% w/w dimethyl sulfoxide;
waiting for the treated area to dry;Read The Full CaseNot a Lexis Advance subscriber? Try it out for free.
Full case includes Shepard's, Headnotes, Legal Analytics from Lex Machina, and more.
940 F.3d 680 *; 2019 U.S. App. LEXIS 30332 **; 2019 U.S.P.Q.2D (BNA) 388801; 2019 WL 5076226
HZNP MEDICINES LLC, HORIZON PHARMA USA, INC., Plaintiffs-Appellants v. ACTAVIS LABORATORIES UT, INC., Defendant-Cross-Appellant
Subsequent History: Judgment entered by HZNP Meds. LLC v. Actavis Labs. UT, Inc., 2019 U.S. App. LEXIS 30348 (Fed. Cir., Oct. 10, 2019)
Prior History: [**1] Appeals from the United States District Court for the District of New Jersey in Nos. 1:14-cv-07992-NLH-AMD, 1:15-cv-05025-NLH-AMD, 1:15-cv-06131-NLH-AMD, 1:15-cv-06989-NLH-AMD, 1:15-cv-07742-NLH-AMD, 1:16-cv-00645-NLH-AMD, Judge Noel Lawrence Hillman.
Horizon Pharma Ir. Ltd. v. Actavis Labs., UT, Inc., 2017 U.S. Dist. LEXIS 77440 (D.N.J., May 12, 2017)
district court, consisting, invention, impurity, drying, patents, properties, novel, indefinite, specification, infringement, label, diclofenac, composition, ingredients, knee, sodium, invalid, induce, degradation, prior art, patient, instructions, medication, sunscreen, method-of-use, repellant, insect, stability, viscosity
Patent Law, Infringement Actions, Claim Interpretation, Jurisdiction & Review, Standards of Review, De Novo Review, Claims & Specifications, Specifications, Definiteness, Constitutional Law, Congressional Duties & Powers, Copyright & Patent Clause, Description Requirement, Civil Procedure, Judgments, Summary Judgment, Entitlement as Matter of Law, Appeals, Summary Judgment Review, Standards of Review, Evidentiary Considerations, Business & Corporate Compliance, Infringing Acts, Indirect Infringement, Clearly Erroneous Review, Nonobviousness, Evidence, Fact & Law Issues